Ratings Green Thumb Industries Inc.

Equities

GTII

CA39342L1085

Market Closed - Canadian Securities Exchange Other stock markets 03:59:58 2024-04-24 pm EDT			5-day change	1st Jan Change
16.83 ^CAD	0.00%		-7.48%	+13.18%

Apr. 24	RISE Dispensaries Owned by Green Thumb Industries Inc. Continues Its Florida Retail Expansion with Opening of RISE Dispensary Wesley Chapel, Its 16Th Florida Location	CI
Mar. 27	Green Thumb Industries Insider Sold Shares Worth $258,256, According to a Recent SEC Filing	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 61.95 times its estimated earnings per share for the ongoing year.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GREEN THUMB INDUSTRIES INC.	+13.18%	2.91B		D+
VERANO HOLDINGS CORP.	+19.73%	1.77B		-
GLASS HOUSE BRANDS INC.	+83.09%	620M		-
HIGH TIDE INC.	+30.52%	161M		-
CANTOURAGE GROUP SE	+16.30%	111M	-	-
MARIMED INC.	-5.93%	98.07M		-
NOVA CANNABIS INC.	+58.43%	58.91M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes